The primary outcomes of the study were (i) the prevalence of HPV types at baseline, (ii) the detection rate (DR) and positive predictive value (PPV) for histologically confirmed CIN3+ (any episode in the 2 years after baseline) of HPV16, HPV18 and non16/18HPV, and (iii) the sensitivity for CIN3+ and number of colposcopies needed for lesion detection. Histologically confirmed CIN2+ was a secondary outcome of the study.
The parameters listed below were calculated for HPV16, HPV18 and non16/18HPV groups.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.